GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

The new data comes shortly after GSK had more good news in its respiratory portfolio, when Nucala was able to achieve a significant reduction in the annualised rate of moderate or severe ...

UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive ... Mepolizumab (SB240563, Bosatria, Nucala, Xinkelai) is an anti-interleukin-5 (IL-5) recombinant ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India.

GSK Stock Performance NYSE GSK opened at $34.08 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 1-year low of $31.72 and ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Credit: megaflopp/Shutterstock. The European Commission (EC) has approved GSK’s Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment ...

Teva Pharmaceutical Industries Ltd. ADR-0.95% $24.61B ...